Mitochondrial dysfunction and risk of cancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Mitochondrial dysfunction and risk of cancer. / Lund, M; Melbye, M; Diaz, L J; Dunø, M.; Wohlfahrt, J; Vissing, J.

I: B J C, Bind 112, Nr. 6, 2015, s. 1134-40.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Lund, M, Melbye, M, Diaz, LJ, Dunø, M, Wohlfahrt, J & Vissing, J 2015, 'Mitochondrial dysfunction and risk of cancer', B J C, bind 112, nr. 6, s. 1134-40. https://doi.org/10.1038/bjc.2015.66

APA

Lund, M., Melbye, M., Diaz, L. J., Dunø, M., Wohlfahrt, J., & Vissing, J. (2015). Mitochondrial dysfunction and risk of cancer. B J C, 112(6), 1134-40. https://doi.org/10.1038/bjc.2015.66

Vancouver

Lund M, Melbye M, Diaz LJ, Dunø M, Wohlfahrt J, Vissing J. Mitochondrial dysfunction and risk of cancer. B J C. 2015;112(6):1134-40. https://doi.org/10.1038/bjc.2015.66

Author

Lund, M ; Melbye, M ; Diaz, L J ; Dunø, M. ; Wohlfahrt, J ; Vissing, J. / Mitochondrial dysfunction and risk of cancer. I: B J C. 2015 ; Bind 112, Nr. 6. s. 1134-40.

Bibtex

@article{7ceb149ba30f4561bdf67495e5ecfb72,
title = "Mitochondrial dysfunction and risk of cancer",
abstract = "BACKGROUND: Mitochondrial mutations are commonly reported in tumours, but it is unclear whether impaired mitochondrial function per se is a cause or consequence of cancer. To elucidate this, we examined the risk of cancer in a nationwide cohort of patients with mitochondrial dysfunction.METHODS: We used nationwide results on genetic testing for mitochondrial disease and the Danish Civil Registration System, to construct a cohort of 311 patients with mitochondrial dysfunction. A total of 177 cohort members were identified from genetic testing and 134 genetically untested cohort members were matrilineal relatives to a cohort member with a genetically confirmed maternally inherited mDNA mutation. Information on cancer was obtained by linkage to the Danish Cancer Register. Standardised incidence ratios (SIRs) were used to assess the relative risk of cancer.RESULTS: During 7334 person-years of follow-up, 19 subjects developed a primary cancer. The corresponding SIR for any primary cancer was 1.06 (95% confidence interval 0.68-1.63). Subgroup analyses according to mutational subtype yielded similar results, for example, a SIR of 0.94 (95% CI 0.53 to 1.67) for the m.3243A>G maternally inherited mDNA mutation, cases=13.CONCLUSIONS: Patients with mitochondrial dysfunction do not appear to be at increased risk of cancer compared with the general population.",
keywords = "Adolescent, Adult, Cohort Studies, DNA, Mitochondrial, Female, Genetic Testing, Humans, Incidence, Male, Middle Aged, Mitochondria, Mitochondrial Diseases, Mutation, Neoplasms, Risk, Risk Factors, Young Adult",
author = "M Lund and M Melbye and Diaz, {L J} and M. Dun{\o} and J Wohlfahrt and J Vissing",
year = "2015",
doi = "10.1038/bjc.2015.66",
language = "English",
volume = "112",
pages = "1134--40",
journal = "The British journal of cancer. Supplement",
issn = "0007-0920",
publisher = "nature publishing group",
number = "6",

}

RIS

TY - JOUR

T1 - Mitochondrial dysfunction and risk of cancer

AU - Lund, M

AU - Melbye, M

AU - Diaz, L J

AU - Dunø, M.

AU - Wohlfahrt, J

AU - Vissing, J

PY - 2015

Y1 - 2015

N2 - BACKGROUND: Mitochondrial mutations are commonly reported in tumours, but it is unclear whether impaired mitochondrial function per se is a cause or consequence of cancer. To elucidate this, we examined the risk of cancer in a nationwide cohort of patients with mitochondrial dysfunction.METHODS: We used nationwide results on genetic testing for mitochondrial disease and the Danish Civil Registration System, to construct a cohort of 311 patients with mitochondrial dysfunction. A total of 177 cohort members were identified from genetic testing and 134 genetically untested cohort members were matrilineal relatives to a cohort member with a genetically confirmed maternally inherited mDNA mutation. Information on cancer was obtained by linkage to the Danish Cancer Register. Standardised incidence ratios (SIRs) were used to assess the relative risk of cancer.RESULTS: During 7334 person-years of follow-up, 19 subjects developed a primary cancer. The corresponding SIR for any primary cancer was 1.06 (95% confidence interval 0.68-1.63). Subgroup analyses according to mutational subtype yielded similar results, for example, a SIR of 0.94 (95% CI 0.53 to 1.67) for the m.3243A>G maternally inherited mDNA mutation, cases=13.CONCLUSIONS: Patients with mitochondrial dysfunction do not appear to be at increased risk of cancer compared with the general population.

AB - BACKGROUND: Mitochondrial mutations are commonly reported in tumours, but it is unclear whether impaired mitochondrial function per se is a cause or consequence of cancer. To elucidate this, we examined the risk of cancer in a nationwide cohort of patients with mitochondrial dysfunction.METHODS: We used nationwide results on genetic testing for mitochondrial disease and the Danish Civil Registration System, to construct a cohort of 311 patients with mitochondrial dysfunction. A total of 177 cohort members were identified from genetic testing and 134 genetically untested cohort members were matrilineal relatives to a cohort member with a genetically confirmed maternally inherited mDNA mutation. Information on cancer was obtained by linkage to the Danish Cancer Register. Standardised incidence ratios (SIRs) were used to assess the relative risk of cancer.RESULTS: During 7334 person-years of follow-up, 19 subjects developed a primary cancer. The corresponding SIR for any primary cancer was 1.06 (95% confidence interval 0.68-1.63). Subgroup analyses according to mutational subtype yielded similar results, for example, a SIR of 0.94 (95% CI 0.53 to 1.67) for the m.3243A>G maternally inherited mDNA mutation, cases=13.CONCLUSIONS: Patients with mitochondrial dysfunction do not appear to be at increased risk of cancer compared with the general population.

KW - Adolescent

KW - Adult

KW - Cohort Studies

KW - DNA, Mitochondrial

KW - Female

KW - Genetic Testing

KW - Humans

KW - Incidence

KW - Male

KW - Middle Aged

KW - Mitochondria

KW - Mitochondrial Diseases

KW - Mutation

KW - Neoplasms

KW - Risk

KW - Risk Factors

KW - Young Adult

U2 - 10.1038/bjc.2015.66

DO - 10.1038/bjc.2015.66

M3 - Journal article

C2 - 25742477

VL - 112

SP - 1134

EP - 1140

JO - The British journal of cancer. Supplement

JF - The British journal of cancer. Supplement

SN - 0007-0920

IS - 6

ER -

ID: 161414313